General Information of Drug (ID: DMC7XDN)

Drug Name
Alprazolam Drug Info
Synonyms
Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Approved [1] , [2]
Epilepsy 8A60-8A68 Phase 2 [3]
Therapeutic Class
Hypnotics and Sedatives
Cross-matching ID
PubChem CID
2118
ChEBI ID
CHEBI:2611
CAS Number
CAS 28981-97-7
TTD Drug ID
DMC7XDN
VARIDT Drug ID
DR01197
INTEDE Drug ID
DR0075
ACDINA Drug ID
D00024

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Translocator protein (TSPO) TTPTXIN TSPO_HUMAN Agonist [4] , [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [6]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Approved [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Approved [8]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Approved [9]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Translocator protein (TSPO) DTT TSPO 7.51 8.89 7.64 8.008
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 10.08 7.207 5.403 9.211
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 11.76 5.931 6.164 9.423
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Anxiety disorder
ICD Disease Classification 6B00-6B0Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Translocator protein (TSPO) DTT TSPO 3.93E-10 0.43 1.02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7111).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074046.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
5 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
6 No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7.
7 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8 Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70.
9 Drug Interactions Flockhart Table